Off the wire
IMF growth forecasts biased: Argentine, Bolivian officials  • Record-breaking heat fuels early bushfires in Australia: institute  • China's economic growth solid: Australian official  • China's top graft-buster exposes decadent officials  • 20 nations vow to fight against maritime piracy  • Audi, Volkswagen to conduct voluntary recalls in Australia  • Roundup: Fed officials see rates liftoff in sight this year  • Spotlight: IMF confident of China's economy, highlights structural change, labor productivity  • China's vehicle-purchase tax cut to benefit buyers, automakers: Moody's  • Sri Lankan president vows to continue friendly policy toward China  
You are here:   Home

Brazil closer to French-made dengue vaccine approval

Xinhua, October 9, 2015 Adjust font size:

The Brazilian National Biosafety Technical Commission (CTNBio) approved on Thursday the commercial release of a vaccine against dengue fever.

The CTNBio approval is a step forward, but the vaccine still needs to be approved by other bodies, including Brazilian National Health Surveillance Agency (Anvisa).

During clinical trials, the vaccine reduced 60.8 percent of dengue fever cases in a group of 21,000 people in Latin America and 56 percent in a group of 10,000 volunteers in Asia.

Dengue fever, a potentially lethal endemic disease that affects many tropical countries, is a significant problem in Brazil, and the year of 2015 is shaping up to be a particularly bad year.

From January to August, 1.4 million cases of dengue were registered in the country, and the number of Dengue-caused deaths reached a record-high of 693 people in the same period.

The vaccine is made by the French multinational pharmaceutical company Sanofi Pasteur but there are other labs attempting to make their own vaccine, including two local institutions: the Oswaldo Cruz Foundation, one of the leading public health research facilities in the world, and the Butantan Institute, responsible for most vaccines used in Brazil and a leader in the study of poisonous animals. Endi